Fertility Preservation for Breast Cancer Patients

ABSTRACT

Breast cancer is the most common neoplasm in women and accounts for 26% (182,460) of all new cancer cases among women. With the use of screening mammography and advancement in other diagnostic modalities, many cases of breast cancer now can be diagnosed and treated at early stages of the disease. Unfortunately, adjuvant chemotherapy regimens commonly used in the treatment of breast cancer may cause premature ovarian failure due to their cytotoxic effects on the germ cells in the ovary. Therefore preservation of fertility in breast cancer survivors at reproductive age has become an important quality of life issue. Fertility preservation is a recently emerged field of reproductive medicine that may help protect the reproductive capability of the cancer survivors and allow them to have children in the future. Embryo freezing is the most established fertility preservation strategy. But conventional ovarian stimulation protocols are contraindicated in breast cancer patients because of the rise of estrogen and its metabolites to supraphysiological levels. Recently developed ovarian stimulation protocols with aromatase inhibitor letrozole and tamoxifen appear to provide a safe stimulation with endogenous estrogen levels comparable with those achieved in the natural cycle. Oocyte freezing can be considered in single women and in those who do not wish donor sperm. Ovarian tissue freezing could also be an option in breast cancer patients who do not wish or have a time for an in vitro fertilization cycle, which requires 10 to 14 days of ovarian stimulation.

KEYWORDS

Breast cancer - chemotherapy - fertility preservation - premature ovarian failure

REFERENCES

• 1 Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2008.  CA Cancer J Clin. 2008;  58(2) 71-96
• 2 Hayat M J, Howlader N, Reichman M E, Edwards B K. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.  Oncologist. 2007;  12(1) 20-37
• 3 Jemal A, Ward E, Thun M J. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.  Breast Cancer Res. 2007;  9(3) R28
• 4 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.  Lancet. 2005;  365(9472) 1687-1717
• 5 Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function.  Cancer. 2007;  110(10) 2222-2229
• 6 Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy.  Oncologist. 2006;  11(5) 422-434
• 7 Oktem O, Oktay K. The ovary: anatomy and function throughout human life.  Ann N Y Acad Sci. 2008;  1127 1-9
• 8 Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve.  Cancer Res. 2007;  67(21) 10159-10162
• 9 Plowchalk D R, Mattison D R. Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide.  Toxicol Appl Pharmacol. 1991;  107(3) 472-481
• 10 Bines J, Oleske D M, Cobleigh M A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.  J Clin Oncol. 1996;  14(5) 1718-1729
• 11 Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.  Fertil Steril. 2008;  90(5) 1635-1639
• 12 van Rooij I A, Broekmans F J, te Velde E R et al.. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve.  Hum Reprod. 2002;  17(12) 3065-3071
• 13 Gruijters M J, Visser J A, Durlinger A L, Themmen A P. Anti-Müllerian hormone and its role in ovarian function.  Mol Cell Endocrinol. 2003;  211(1-2) 85-90
• 14 Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles.  Hum Reprod. 2006;  21(8) 2022-2026
• 15 Knauff E A, Eijkemans M J, Lambalk C B Dutch Premature Ovarian Failure Consortium et al. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure.  J Clin Endocrinol Metab. 2009;  94(3) 786-792
• 16 Oktay K, Oktem O, Reh A, Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer.  J Clin Oncol. 2006;  24(24) 4044-4046
• 17 Partridge A H, Ruddy K J, Gelber S et al.. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.  Fertil Steril. 2009;  , April 29 (Epub ahead of print)
• 18 Partridge A, Gelber S, Gelber R D, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.  Eur J Cancer. 2007;  43(11) 1646-1653
• 19 Kil W J, Ahn S D, Shin S S et al.. Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients.  Breast Cancer Res Treat. 2006;  96(3) 245-250
• 20 Parulekar W R, Day A G, Ottaway J A National Cancer Institute of Canada Clinical Trials Group et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA. 5.  J Clin Oncol. 2005;  23(25) 6002-6008
• 21 Hortobagyi G N, Buzdar A U, Marcus C E, Smith T L. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute.  NCI Monogr. 1986;  (1) 105-109
• 22 Tham Y L, Sexton K, Weiss H, Elledge R, Friedman L C, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.  Am J Clin Oncol. 2007;  30(2) 126-132
• 23 Berliere M, Dalenc F, Malingret N et al.. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel.  BMC Cancer. 2008;  8 56
• 24 Nabholtz J, Pienkowski T, Mackey J et al.. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study.  Proc Am Soc Clin Oncol. 2002;  21 36a
• 25 Swain S M, Land S R, Ritter M W et al.. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.  Breast Cancer Res Treat. 2009;  113 315-320
• 26 Han H S, Ro J, Lee K S et al.. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.  Breast Cancer Res Treat. 2009;  115(2) 335-342
• 27 Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.  Cochrane Database Syst Rev. 2008;  (4) CD004562
• 28 Cuzick J, Ambroisine L, Davidson N et al.. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.  Lancet. 2007;  369(9574) 1711-1723
• 29 Jonat W, Kaufmann M, Sauerbrei W Zoladex Early Breast Cancer Research Association Study et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.  J Clin Oncol. 2002;  20(24) 4628-4635
• 30 Hackshaw A, Baum M, Fornander T et al.. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.  J Natl Cancer Inst. 2009;  101(5) 341-349
• 31 Lee S J, Schover L R, Partridge A H American Society of Clinical Oncology et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients.  J Clin Oncol. 2006;  24(18) 2917-2931
• 32 Oktem O, Oktay K. Preservation of menstrual function in adolescent and young females.  Ann N Y Acad Sci.. 2008;  1135 237-243
• 33 Azim A A, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.  J Clin Oncol. 2008;  26(16) 2630-2635
• 34 Chen C. Pregnancy after human oocyte cryopreservation.  Lancet. 1986;  1(8486) 884-886
• 35 Oktay K, Cil A P, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis.  Fertil Steril. 2006;  86(1) 70-80
• 36 Patrizio P, Sakkas D. From oocyte to baby: a clinical evaluation of the biological efficiency of in vitro fertilization.  Fertil Steril. 2009;  91(4) 1061-1066
• 37 Donnez J, Dolmans M M, Demylle D et al.. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue.  Lancet. 2004;  364(9443) 1405-1410
• 38 Meirow D, Levron J, Eldar-Geva T et al.. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy.  N Engl J Med. 2005;  353(3) 318-321
• 39 Demeestere I, Simon P, Buxant F et al.. Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report.  Hum Reprod. 2006;  21(8) 2010-2014
• 40 Oktay K. Spontaneous conceptions and live birth after heterotopic ovarian transplantation: is there a germline stem cell connection?.  Hum Reprod. 2006;  21(6) 1345-1348
• 41 Curtin J P, Barakat R R, Hoskins W J. Ovarian disease in women with breast cancer.  Obstet Gynecol. 1994;  84(3) 449-452